Congestive Heart Failure And CoQ10

Since the 1960???s there have been numerous controlled clinical trials concerning the relationship between congestive heart failure and Coenzyme Q10 (CoQ10). As its name implies CoQ10 is a coenzyme that is necessary for the proper functioning of other substances, one of the most important of which is ATP (adenosine triphosphate). ATP is necessary for the production of cellular energy. By proxy CoQ10 is likewise essential for this process.

Clinical trials have attempted to study the relationship between CoQ10 and many chronic diseases including, but not limited to, heart disease, cancer and AIDS. But heart disease has gained the most attention; congestive heart failure being one of the primary subjects. Because heart muscle cells require so much energy to function and CoQ10 is at the core of the cellular energy process it makes sense to suspect that congestive heart failure might be linked to CoQ10 deficiency. With that theory in mind many studies like the ones that follow have been conducted. These trials have been presented in this essay in thumbnail format.

One early Japanese trial (1972) involved 197 patients with varying levels of severity of cardiac failure. The study reported significant improvement of cardiac function supplementing with 30 mg per day of CoQ10. Another Japanese study demonstrated similar results with 38 patients also supplementing with 30 mg. In 1985 a U.S. clinical study prescribed daily supplementation with 100 mg of the coenzyme for treatment periods of three months for patients with low ejection fraction measurements. The ejection fraction is the measure of the heart???s ability to pump blood. A low ejection fraction is a classic symptom of congestive heart failure. Again, significant improvements in heart function were reported. Other clinical trials followed prescribing the same level of supplementation with similar results.

Studies in the early 1990s showed improvement for patients suffering from ischemic cardiomyopathy (a low oxygen state usually due to obstruction) with supplemental levels of 200 mg per day. Supplementing with 100 mg per day demonstrated improvement for patients suffering from idiopathic dilated cardiomyopathy, an enlarged heart syndrome of unknown cause.

One of the largest trials of the 1990s involves 641 patients randomly divided into two groups. The first group received a placebo. The other group received CoQ10 supplements. During the one-year follow-up period 118 patients in the placebo group were hospitalized for heart failure compared to 73 in the group that received the supplements.

All of the preceding trials were relatively short-term studies. The level of improvement among patients varied depending on how long they had been suffering from some aspect of congestive heart failure. Through the years it has become increasing clear that the greatest improvements were shown in patients that had suffered from their condition the least amount of time.

In other words, the longer a person had been suffering from the disease before he or she received CoQ10 treatments the less improvement was demonstrated. People who had received treatments early in the development of the disease showed the most dramatic improvement often returning to normal heart function. Long-term sufferers received less relief and were less likely to return to full heart function. Whatever the reasons for this disparity in health improvement, it demonstrates the importance of receiving treatment as early as possible.

But what about long-term studies? Do they show the same marked improvement with similar treatment? In the short-term trials it was apparent that even high level supplementing with CoQ10 seemed to produce no ill effects. In order to determine if this is only true for short durations a number of long-term studies were conducted.

In 1990 observations were published concerning 126 patients with dilated cardiomyopathy. Unlike previously noted studies this one followed the patients??? progress for six years. Long-term benefits from CoQ10 supplementing were noticed with no harmful side effects. Similar observations were made in a trial involving 2,664 patients treated with CoQ10 at levels up to 150 mg per day.

A 1994 study involving 424 patients with a variety of myocardial (refers to the heart's muscle mass) diseases. Among these conditions were the following: Valvular heart disease (pertaining to dysfunction of heart valves), hypertension, diastolic dysfunction (failure of the heart to properly refill itself with blood), dilated cardiomyopathy (group of disorders where the heart muscle is weakened and enlarged and cannot pump effectively) and ischemic cardiomyopathy (low oxygen state usually due to obstruction of the arterial blood supply).

Patients were treated with an average of 240 mg of CoQ10 daily during their treatment period. They were then followed-up for up to eight years with an average follow-up period of 18 months. Overall results demonstrated measurable cardiac improvements in one month with maximum improvements at about six months. With continued CoQ10 treatment the improvement in most patients was sustained. However, discontinuing the treatment usually resulted in a decline of cardiac function with eventual return to pre-treatment conditions.

As always in the medical community many more studies will need to be conducted to determine the future of CoQ10 treatment. However, the research to date seems to support CoQ10 as a viable treatment for many diseases that are caused or exacerbated by inadequate production of cellular energy.

Greg holds degrees in science, divinity and philosophy and is currently an I.T. developer.

http://www.optimal-heart-health.com/coq10.html

last minute cleaning help Arlington Heights ..

In The News:

Fox News Digital's artificial intelligence newsletter digs into a robot in Russia that faceplanted, George Clooney's alarm and OpenAI's rivalry with the New York Times.

Major data breach at Conduent exposes personal information of 10+ million people. Government contractor hit by cyberattack affecting Medicaid, child support systems.

Texas startup Janta Power raises $5.5M for innovative vertical solar towers that generate 50% more energy than traditional panels while using just one-third the land.

NASA's twin ESCAPADE spacecraft launched aboard Blue Origin's New Glenn rocket Thursday afternoon from Cape Canaveral, beginning their journey to Mars with arrival expected in 2027.

Learn how to set email reminders on iPhone and Android so you never forget to reply again. Simple built-in features help you stay organized and on top of messages.

Discover how Apple's passkeys revolutionize Mac security by replacing vulnerable passwords with biometric authentication and encryption for ultimate protection.

New survey reveals 78% of parents fear AI scams targeting their kids, yet nearly half haven't discussed these threats. Learn why this dangerous gap exists.

Chrome now autofills passport and driver's license info automatically. Google's latest browser update adds official document support with encryption and user control.

Scammers impersonate Department of Veterans Affairs employees claiming veterans owe money, but real VA communications only direct to VA.gov or official channels.

The AltoVolo Sigma hybrid-electric aircraft flies 500 miles at 220 mph while operating 80% quieter than helicopters, featuring safety systems and compact design.

Google search scam alert: fake customer service numbers can give scammers remote control of your phone. Learn how to spot these traps and protect yourself.

Electric vehicles overtake gas cars in total CO2 savings after just two years of driving, with emissions benefits growing over time as power grids get cleaner.

Louvre Museum reportedly used "Louvre" as password for surveillance system during $100M jewel heist. Learn how weak passwords put even famous institutions at risk.

Bipartisan AI jobs bill from Sens. Hawley and Warner would require companies to report AI-related layoffs and hiring to Department of Labor quarterly.

Joe A. from Shelton, Connecticut, lost $228,000 to a ZAP Solutions cryptocurrency investment scam after his divorce, highlighting rising online fraud.

AI-powered autonomous trucks from Waabi and Volvo target U.S. freight driver shortage with Level 4 self-driving technology and NVIDIA computing platform integration.

Survive flight disruptions with expert travel tips: Book early morning flights, download airline apps and know your refund rights during service cuts.

Apple's iOS 26.1 update delivers major security fixes, performance boosts and enhanced privacy controls for your iPhone. Discover why updating now protects your data.

Russian hackers use fake CAPTCHA tests to spread dangerous malware targeting governments and journalists. Learn how to protect yourself from these deceptive attacks.

Stay up to date on the latest AI technology advancements and learn about the challenges and opportunities AI presents now and for the future.

Miami-Dade debuts America's first autonomous police SUV with AI cameras, drone deployment and real-time crime detection in groundbreaking law enforcement pilot.

Bank impostor scams cost Americans $2.9 billion as criminals use AI voices and caller ID spoofing to steal life savings. Learn nine essential fraud protection tips.

Foreign-owned apps secretly harvest personal data from seniors, making them prime targets for scams. Learn how to protect your privacy and stop data brokers today.

Sens. Josh Hawley and Richard Blumenthal introduce bipartisan GUARD Act to protect minors from AI chatbots through mandatory age verification and disclosure requirements.

Ghost-tapping scammers exploit wireless technology to drain accounts through small transactions, but RFID-blocking wallets and transaction alerts can protect you.

Congestive Heart Failure And CoQ10

Nutritional Supplements